2. Search Result
Search Result
Results for "

Clofibrate

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0287
    Clofibrate
    2 Publications Verification

    		 PPAR Metabolic Disease
    Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.
    Clofibrate
  • HY-B0287R
    Clofibrate (Standard)
    2 Publications Verification

    		 Reference Standards PPAR Metabolic Disease
    Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.
    Clofibrate (Standard)
  • HY-107348
    Etofylline clofibrate

    		Prostaglandin Receptor Cardiovascular Disease
    Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2 .
    Etofylline clofibrate
  • HY-B0287S
    Clofibrate-d4

    		PPAR Metabolic Disease
    Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
    Clofibrate-d4
  • HY-107348R
    Etofylline clofibrate (Standard)

    		Prostaglandin Receptor Cardiovascular Disease
    Etofylline clofibrate (Standard) is the analytical standard of Etofylline clofibrate. This product is intended for research and analytical applications. Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2 .
    Etofylline clofibrate (Standard)
  • HY-156977
    Sitofibrate

    		PPAR Cardiovascular Disease
    Sitofibrate is a Clofibrate (HY-B0287) derivative. Sitofibrate is aperoxisome proliferator activated receptor-α (PPAR-α) agonist. Sitofibrate is an antihyperlipidemic agent .
    Sitofibrate
  • HY-14998
    Halofenate

    MK 185

    		 β-catenin PPAR Wnt Endocrinology
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
    Halofenate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: